Reports Q2 revenue $3.5M vs. $1M last year. “Abeona is at a pivotal moment in our history as we are busy finalizing and planning to soon submit the BLA for EB-101 for the treatment of recessive dystrophic epidermolysis bullosa,” said Vish Seshadri, Chief Executive Officer of Abeona. “The recent capital raise allows us to initiate preparations for the commercial launch of EB-101 in the U.S., while also extending our cash runway well beyond the anticipated regulatory approval time for EB-101.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABEO:
- Abeona Therapeutics Reports Second Quarter 2023 Financial Results
- ABEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
- Abeona submits briefing package to FDA for pre-BLA meeting for EB-101
- Abeona Therapeutics joins Rare Disease Company Coalition